NEW YORK — Irish diagnostics firm Serosep said that it has signed a US distribution deal for its EntericBio Dx gastrointestinal pathogen panel with Quidel.
The panel, which received US Food and Drug Administration clearance earlier this year, includes tests for salmonella, Shiga toxin-producing Escherichia coli, Shigella, Campylobacter, Giardia, Entamoeba histolytica, and Vibrio.
Under the terms of the deal, San Diego-based Quidel will exclusively distribute the test in the US. Additional terms were not disclosed.
"EntericBio is now the most widely used gastrointestinal molecular diagnostic test, both in Ireland and the UK," Serosep CEO Dermot Scanlon said in a statement. "Serosep is hoping to replicate this success in the USA through its cooperation with Quidel."